Funding to progress Chroma’s single-dose epigenetic modifying therapies and help growth of novel genetic drugs platform designed to allow exact gene regulation whereas preserving genomic integrity
Financing led by GVwith participation from ARCH Enterprise Companions, DCVC Bio, Mubadala Capital, Sixth Road, and all present traders
CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ — Chroma MedicationInc., (Chroma) a genomic drugs firm pioneering single-dose epigenetic modifying therapeutics, right this moment introduced the completion of a $135 million Sequence B financing led by GV (Google Ventures), with participation from extra new traders ARCH Enterprise Companions, DCVC Bio, Mubadala Capital, Sixth Road, and all present traders, together with Alexandria Enterprise Investments, Atlas Enterprise, Casdin Capital, Cormorant Asset Administration, Janus Henderson Traders, Newpath Companions, Omega Funds, Osage College Companions, Sofinnova Companions, T Rowe Value, and Wellington Administration. The financing will help the development of Chroma’s therapeutic applications towards the clinic, and continued funding within the firm’s core epigenetic modifying platform.
“Within the 12 months since launch, we’ve got made important progress in advancing the pioneering work of our scientific founders in direction of harnessing the ability of the cell’s epigenome to manage gene expression and creating a sturdy portfolio of single-dose epigenetic modifying therapeutics,” stated Catherine Stehman-Breen, MD, CEO of Chroma. “We’re grateful to this distinctive syndicate of traders, whose dedication permits our ongoing drive to introduce this new class of precision genomic medicines with healing potential to sufferers with critical diseases.”
Present gene modifying approaches regulate gene expression by chopping or nicking DNA, introducing dangers related to leveraging unpredictable DNA restore pathways. Chroma’s single-dose epigenetic editors harness the cells’ innate mechanism for gene regulation to exactly and durably silence, activate, and multiplex genes utilizing a single platform, with out altering the underlying DNA sequence. This groundbreaking method permits Chroma to extra successfully handle a variety of illnesses and to focus on a number of pathways for complicated illnesses.
“Epigenetic modifying opens the potential of pursuing targets on the genome beforehand intractable with different therapeutic modalities; this contains the flexibility to focus on each protein coding and non-coding RNAs,” stated Vic Myer, Ph.D., CSO of Chroma. “Our method permits exact regulation whereas avoiding break-induced mutations, translocations, and rearrangements related to different applied sciences, eradicating limitations on the variety of simultaneous edits which are potential.”
“Genomic drugs is an thrilling and fast-evolving area, and epigenetic modifying has emerged as a promising new frontier for gene regulation,” stated Issi Rozen, Enterprise Companions, GV. “Chroma’s know-how permits sturdy modulation of gene expression—each particular person genes and a number of genes directly—offering probably transformative remedies for sufferers dwelling with critical illnesses.”
About Chroma Medication
Chroma Medication is a biotechnology firm pioneering a brand new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to ship exact, programmable single-dose therapeutics whereas preserving genomic integrity. The corporate was based by the world’s foremost consultants in genomic analysis and is led by a veteran group of business leaders and scientists with deep expertise in genomic drugs, drug discovery, and growth. For extra data, please go to chromamedicine.com or observe the corporate on LinkedIn and Twitter.
SOURCE Chroma Medication